Background: The use of bacterial vaccines as a potential Bacterial-Based Cancer Therapy (BBCT) presents an innovative approach, transforming these vaccines into multifunctional tools capable of serving dual roles in medicine.
Materials And Methods: This study aimed to conduct in vitro, immunity-independent experiments to investigate the anticancer properties of vaccine-derived bacterial toxoids on various cancer cell lines. Six concentrations of the DTP vaccine (5 x 10-4, 25 x 10-5, 125 x 10-6, 625 x 10-7, 312 x 10-7, and 15 x 10-6 µg/ml) were tested on two cancer cell lines (SKG and HCAM) and a normal Rat Embryonic Fibroblast (REF) cell line. The cytotoxic effects were evaluated using the Crystal Violet assay to determine the percentage of cell death for each toxoid concentration, leading to the calculation of IC50 values. Apoptotic effects and other cytopathological changes were observed under an inverted microscope.
Results: The findings revealed significant toxic effects of the bacterial toxoid on the SKG and HCAM cancer cell lines (p < 0.001). In contrast, the toxic effects on the normal REF cell line were evident only at the highest toxoid concentrations. Microscopic analysis showed marked cytological changes in cancer cells treated with the toxoid, with minimal impact on normal cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.31557/APJCP.2025.26.1.233 | DOI Listing |
J Pharm Pharmacol
January 2025
Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Objectives: PD15, a novel natural steroidal saponin extracted from the rhizomes of Paris delavayi Franchet, has demonstrated a strong cytotoxic effect against HepG2 and U87MG cells. However, its therapeutic effects on colorectal cancer (CRC) and the underlying molecular mechanisms remain unclear.
Methods: MTT assay, clonogenic assay, Hoechst 33258 staining, flow cytometry, molecular docking, and western blot were used to investigate the mechanism of PD15 in HCT116 cell lines.
Am J Hosp Palliat Care
January 2025
Department of Pediatrics, University of Chicago, Comer Children's Hospital, Chicago, IL, USA.
Pediatric neuro-oncology patients have one of the highest mortality rates among all children with cancer. Our study examines the potential relationship between palliative care consultation and intensity of in-hospital care and determines if racial and ethnic differences are associated with palliative care consultations during their terminal admission. Retrospective observational study using the Pediatric Health Information System (PHIS) database with data from U.
View Article and Find Full Text PDFJ Clin Oncol
January 2025
Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of China, Shatin, Hong Kong Special Administrative Region, China.
Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of ex20ins+ advanced/metastatic NSCLC.
View Article and Find Full Text PDFAnnu Rev Immunol
January 2025
1Immunity and Cancer, INSERM U932, PSL University, Institut Curie, Paris, France; email:
Mucosal-associated invariant T (MAIT) cells are evolutionarily conserved T cells that recognize microbial metabolites. They are abundant in humans and conserved during mammalian evolution, which suggests that they have important nonredundant functions. In this article, we discuss the evolutionary conservation of MAIT cells and describe their original developmental process.
View Article and Find Full Text PDFClin Cancer Res
January 2025
ACTREC, Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
Purpose: Identifying therapeutic targets for Signet Ring Cell Carcinoma (SRCC) of the colon and rectum is a clinical challenge due to the lack of Patient-Derived Organoids (PDO) or Xenografts (PDX). We present a robust method to establish PDO and PDX models to answer address this unmet need. We demonstrate that these models identify novel therapeutic strategies targeting therapy resistance and peritoneal metastasis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!